---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-328684"
form_type: "8-K/A"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:24:22.827824+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics discloses interim CEO pay and new director committee roles

## Summary
- Interim CEO Iain Ross receives £25,000/month cash for six months, then month-to-month, plus 900,000 option shares vesting over 12 months.
- New director James Ede-Golightly appointed to Remuneration, Audit & Risk, and Nominations Committees; granted 90,000 option shares vesting over 12 months.
- Ross is also eligible for a discretionary cash bonus as determined by the Remuneration Committee.
- Both option grants are under the company's 2023 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001193125-25-328684
- form_type: 8-K/A
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312525328684/0001193125-25-328684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312525328684/sln-20251214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-328684
- JSON: https://secwatch.observer/filing/0001193125-25-328684.json
- Plain text: https://secwatch.observer/filing/0001193125-25-328684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.